NeoGenomics Inc. announced that industry veteran Chris Smith has been appointed as member of the board of directors effective August 15, 2022. Concurrently, Chair of the Board and Interim CEO Lynn Tetrault will resume role as independent Chair of the Board while assisting in the transition of responsibilities. Mr. Smith will join NeoGenomics after serving as CEO of Ortho Clinical Diagnostics (Ortho Clinical) from 2019 to May 2022.

Mr. Smith also successfully guided the company through a combination with Quidel that closed in May 2022. Prior to Ortho Clinical, Mr. Smith served in key executive leadership positions at Cochlear Limited. Having initially joined Cochlear as President of Cochlear Americas in 2004, Mr. Smith helped grow division revenue from $80 million to over $400 million before being named CEO in 2015.

During his tenure as CEO from 2015 to 2018, Mr. Smith oversaw 35% organic improvement in annual revenues and improving profitability. Before joining Cochlear, Mr. Smith served as a CEO in residence at global private equity firm Warburg Pincus and Global Group President at Gyrus Group Plc. Prior to that Smith served in a variety of leadership roles at Abbott, KCI, Prism and Cardinal Health.

Mr. Smith has a Bachelor of Science degree from Texas A&M University. Mr. Smith will be relocating to, and working out of, the NeoGenomics global headquarters in Fort Myers, Florida.